Cargando…
Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study
Background: Chronic active Epstein-Barr virus (CAEBV) infection is one of the EBV-positive T- or NK-cell lymphoproliferative diseases. There is no safe and effective treatment currently and the only proven curable therapy is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The JAK1/2...
Autores principales: | Song, Yue, Wang, Jingshi, Wang, Yini, Wang, Zhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450490/ https://www.ncbi.nlm.nih.gov/pubmed/34552486 http://dx.doi.org/10.3389/fphar.2021.710400 |
Ejemplares similares
-
Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
por: Jin, Zhili, et al.
Publicado: (2019) -
HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center
por: Song, Yue, et al.
Publicado: (2020) -
Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
por: Wei, Na, et al.
Publicado: (2021) -
Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016) -
Development of a Nomogram to Predict the Risk of Chronic Active Epstein-Barr Virus Infection Progressing to Hemophagocytic Lymphohistiocytosis
por: He, Xiaodan, et al.
Publicado: (2022)